ProPhase Labs Operating Income Over Time
| PRPH Stock | USD 0.15 0.01 7.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ProPhase Labs Performance and ProPhase Labs Correlation. Is there potential for Pharmaceuticals market expansion? Will ProPhase introduce new products? Factors like these will boost the valuation of ProPhase Labs. Anticipated expansion of ProPhase directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (23.42) | Revenue Per Share | Quarterly Revenue Growth (0.38) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between ProPhase Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProPhase Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, ProPhase Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare ProPhase Labs and related stocks such as Aytu BioScience, TherapeuticsMD, and Allurion Technologies Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AYTU | (46.9 K) | (56.4 K) | (52.4 K) | (6.3 M) | (7.6 M) | (21.7 M) | (20.1 M) | (19.7 M) | (16.8 M) | (21.1 M) | (58.9 M) | (109.9 M) | (17.1 M) | (1.6 M) | (7.8 M) | (7 M) | (7.4 M) |
| TXMD | 42.6 K | (5.4 M) | (16.1 M) | (25.8 M) | (54 M) | (85.2 M) | (90.3 M) | (77.6 M) | (130.2 M) | (151.2 M) | (155.5 M) | (79.6 M) | 1.2 M | (8.5 M) | (4.8 M) | (4.3 M) | (4.5 M) |
| ALUR | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (12.5 M) | (32 M) | (79.1 M) | (50.2 M) | (45.2 M) | (47.4 M) |
| ERNA | (1.4 M) | (3.3 M) | (1.1 M) | (1.1 M) | (4.7 M) | (6.6 M) | (2.3 M) | (1.4 M) | 464 K | (1.2 M) | (7.2 M) | (113.7 M) | (33.2 M) | (21.1 M) | (15.7 M) | (14.1 M) | (14.8 M) |
| BFRI | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (9.6 M) | (25.2 M) | (18.6 M) | (22.7 M) | (17.2 M) | (15.5 M) | (16.3 M) |
| AEMD | (1.5 K) | (3.1 M) | (3.6 M) | (3.1 M) | (4 M) | (4.4 M) | (6.1 M) | (4.8 M) | (6 M) | (5.9 M) | (7.9 M) | (10.4 M) | (11.9 M) | (12.6 M) | (9.3 M) | (8.4 M) | (8 M) |
| CODX | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (2 M) | (1.7 M) | (4.6 M) | (6.1 M) | (5.9 M) | 41.7 M | 46.1 M | (27 M) | (42.7 M) | (40.1 M) | (36.1 M) | (34.3 M) |
| LNAI | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (116.1 M) | (38.6 M) | (81.6 M) | (189 M) | (170.1 M) | (161.6 M) |
| SBFM | (13.1 K) | (556.2 K) | (706.7 K) | (1.9 M) | (1.8 M) | (780 K) | (993.1 K) | (857.2 K) | (1.2 M) | (641.6 K) | (576.9 K) | (2.4 M) | (27 M) | (4.8 M) | (5.8 M) | (5.2 M) | (5 M) |
ProPhase Labs and related stocks such as Aytu BioScience, TherapeuticsMD, and Allurion Technologies Operating Income description
Operating Income is the amount of profit realized from ProPhase Labs operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ProPhase Labs is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| ProPhase Labs | PRPH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 711 Stewart Avenue, |
| Exchange | NASDAQ Exchange |
USD 0.15
Check out ProPhase Labs Performance and ProPhase Labs Correlation. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
ProPhase Labs technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.